ProShare Advisors
CMPX icon

ProShare Advisors’s Compass Therapeutics CMPX Stock Holding History

ProShare Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.6K Sell
17,167
-1,536
-8% -$4.54K ﹤0.01% 1867
2026
Q1 		$98.9K Sell
18,703
-5,269
-22% -$30.4K ﹤0.01% 1706
2025
Q4 		$129K Buy
23,972
+6,968
+41% +$32.2K ﹤0.01% 1825
2025
Q3 		$59.5K Sell
17,004
-1,791
-10% -$5.66K ﹤0.01% 1918
2025
Q2 		$48.9K Sell
18,795
-3,284
-15% -$6.77K ﹤0.01% 1995
2025
Q1 		$42K Sell
22,079
-6,643
-23% -$17.7K ﹤0.01% 1970
2024
Q4 		$41.6K Buy
28,722
+9,451
+49% +$15.7K ﹤0.01% 2203
2024
Q3 		$35.5K Buy
19,271
+7,048
+58% +$8.79K ﹤0.01% 2015
2024
Q2 		$12.2K Sell
12,223
-4,173
-25% -$6.09K ﹤0.01% 1830
2024
Q1 		$32.5K Buy
16,396
+1,292
+9% +$2.23K ﹤0.01% 1951
2023
Q4 		$23.6K Buy
15,104
+3,248
+27% +$5.62K ﹤0.01% 1913
2023
Q3 		$23.4K Sell
11,856
-12
-0.1% -$30 ﹤0.01% 1777
2023
Q2 		$37.7K Buy
+11,868
New +$37.3K ﹤0.01% 1797

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ProShare Advisors's CMPX Position: Q2 2026 in Review

ProShare Advisors reduced its Compass Therapeutics (CMPX) stake by 8.2% in Q2 2026, selling an estimated $4.54K and leaving 17,167 shares worth $37.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1867.

ProShare Advisors first reported a position in CMPX in Q2 2023 and has held it in 13 quarters since. The position peaked at $129K in Q4 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • ProShare Advisors held 17,167 shares of Compass Therapeutics worth $37.6K as of Q2 2026.
  • ProShare Advisors sold 1,536 Compass Therapeutics shares in Q2 2026, an estimated $4.54K.
  • Compass Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1867 holding.
  • ProShare Advisors first reported a position in Compass Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • ProShare Advisors's Compass Therapeutics position peaked at $129K in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.